Talphera Inc.
Closed
0.75 -2.6
Overview
Share price change
24h
Min
0.73
Max
0.78
Income | 1.2M -2.6M |
|---|---|
Profit margin | -443,600 |
Employees | 12 |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +306.41% upside |
Next Earnings | 13 sie 2026 |
|---|
Market Cap | 35M |
|---|---|
Previous open | 3.35 |
Previous close | 0.75 |
Talphera Inc. Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Talphera Inc. Forecast
Price Target
By TipRanks
306.41% upside
12 Months Forecast
Average 3.17 USD 306.41%
High 3.5 USD
Low 3 USD
Based on 3 Wall Street analysts offering 12 month price targets forTalphera Inc. - Dist in the last 3 months.
Financials
Selling and administration expenses
Pre-tax profit
Sales
Interest expense on debt
Operating profit
$
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
